The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of BRCA genetic testing and subsequent treatment with PARP inhibitors (PARPi) for ederly vs non-elderly women with non-mucinous epithelial ovarian cancer (EOC): A large prospective cohort study from the Australian National Gynaecology Oncology Registry (NGOR).
 
Mahendra Naidoo
No Relationships to Disclose
 
Clare L. Scott
Consulting or Advisory Role - Oncology One
Research Funding - AstraZeneca; Clovis Oncology; Eisai; Sierra Oncology
Patents, Royalties, Other Intellectual Property - Royalty agreement for venetoclax (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Eisai; Epsila Bio; GlaxoSmithKline; MSD Oncology; Sierra Oncology; Takeda
 
Orla McNally
No Relationships to Disclose
 
Rob Rome
No Relationships to Disclose
 
Sharnel Perera
No Relationships to Disclose
 
John Raymond Zalcberg
Leadership - ICON Group; Lipotek
Stock and Other Ownership Interests - Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Madrigal Pharmaceuticals; Moderna Therapeutics; Novavax; Opthea; Orphazyme; Twist Bioscience; UniQure; Zogenix
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; MSD Oncology; Specialised Therapeutics; Targovax; Viatris
Consulting or Advisory Role - 1Globe Health Institute; Alloplex Biotherapeutics Inc; Center for Emerging & Neglected Diseases (CEND); Deciphera; FivePHusion; Genor BioPharma; Lisata; Merck Sharp & Dohme; NOUS Group; Novotech; Revolution Medicines; Specialised Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst)